{"id":"NCT01339091","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","briefTitle":"Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections","officialTitle":"A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Dalbavancin to a Comparator Regiment (Vancomycin and Linezolid) for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2012-09","completion":"2012-11","firstPosted":"2011-04-20","resultsPosted":"2013-12-25","lastUpdate":"2014-01-31"},"enrollment":573,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Abscess","Wound Infection","Surgical Site Infection","Cellulitis"],"interventions":[{"type":"DRUG","name":"Dalbavancin","otherNames":[]},{"type":"DRUG","name":"Vancomycin / Linezolid","otherNames":[]}],"arms":[{"label":"Dalbavancin","type":"EXPERIMENTAL"},{"label":"Vancomycin with possible switch to oral linezolid","type":"ACTIVE_COMPARATOR"}],"summary":"The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a suspected or proven gram-positive bacterial skin or skin structure infection.","primaryOutcome":{"measure":"Early Clinical Efficacy","timeFrame":"48-72 hours after the initiation of study therapy","effectByArm":[{"arm":"Dalbavancin","deltaMin":240,"sd":null},{"arm":"Vancomycin +/- Oral Linezolid","deltaMin":233,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":91,"countries":["United States","Canada","Croatia","Georgia","Germany","Poland","Russia","Ukraine"]},"refs":{"pmids":["34905144","24897082"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":284},"commonTop":["Headache","Nausea","Diarrhoea","Hypertension","Rash"]}}